Virchows Archiv最新文献_第6页

CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation. 有基因突变和无基因突变的浸润性小叶乳腺癌的 CDH1 甲基化分析。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-05-07 DOI: 10.1007/s00428-024-03814-8

Silvia González-Martínez, Viera Horvathova Kajabova, Belén Pérez-Mies, Irene Carretero-Barrio, Tamara Caniego-Casas, David Sarrió, Gema Moreno-Bueno, María Gión, José Perez-García, Javier Cortés, Bozena Smolkova, José Palacios

{"title":"CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation.","authors":"Silvia González-Martínez, Viera Horvathova Kajabova, Belén Pérez-Mies, Irene Carretero-Barrio, Tamara Caniego-Casas, David Sarrió, Gema Moreno-Bueno, María Gión, José Perez-García, Javier Cortés, Bozena Smolkova, José Palacios","doi":"10.1007/s00428-024-03814-8","DOIUrl":"10.1007/s00428-024-03814-8","url":null,"abstract":"The proposed role of CDH1 (E-cadherin gene) methylation as a mechanism of gene inactivation in invasive lobular carcinoma (ILC) remains inconclusive. For many years, CDH1 promoter hypermethylation has been regarded as a mechanism for gene inactivation in ILC. However, this assumption has primarily relied on non-quantitative assays, which have reported CDH1 methylation frequencies ranging from 26 to 93% at CpG sites within the island region. Few studies employing quantitative methods and covering CpG island shores, regions of relatively low CpG density situated proximal to conventional promoter CpGs, have been conducted, revealing lower percentages of methylation ranging from 0 to 51%. Therefore, using the quantitative pyrosequencing method, we examined CDH1 methylation in the island region and shores in E-cadherin deficient ILC cases (15 with CDH1 mutation and 22 non-mutated), 19 cases of invasive breast carcinomas non-special type (IBC-NSTs), and five cases of usual ductal hyperplasia (UDH). Our analysis revealed CDH1 methylation frequencies ranging from 3 to 64%, with no significant increase in methylation levels in any group of ILCs (median = 12%) compared to IBC-NST (median = 15%). In addition, considering the poorly studied association between the number of tumor-infiltrating lymphocytes (TILs) and CDH1 methylation in breast cancer, we undertook a thorough analysis within our dataset. Our findings revealed a positive correlation between CDH1 methylation and the presence of TILs (r = 0.5; p-value < 0.05), shedding light on an aspect of breast cancer biology warranting further investigation. These findings challenge CDH1 methylation as a CDH1 inactivation mechanism in ILC and highlight TILs as a potential confounding factor in gene methylation.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140851566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MUC5AC immunoreactivity in scattered tumor cells is useful for diagnosing CIC-rearranged sarcoma. 散在肿瘤细胞中的 MUC5AC 免疫反应有助于诊断 CIC 重组肉瘤。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-07-06 DOI: 10.1007/s00428-024-03863-z

Shogo Nishino, Naoki Kojima, Hirokazu Sugino, Taisuke Mori, Yasushi Yatabe, Akihiko Yoshida

{"title":"MUC5AC immunoreactivity in scattered tumor cells is useful for diagnosing CIC-rearranged sarcoma.","authors":"Shogo Nishino, Naoki Kojima, Hirokazu Sugino, Taisuke Mori, Yasushi Yatabe, Akihiko Yoshida","doi":"10.1007/s00428-024-03863-z","DOIUrl":"10.1007/s00428-024-03863-z","url":null,"abstract":"CIC-rearranged sarcoma is an aggressive round cell sarcoma, and an alternative ATXN1/ATXN1L fusion has been reported. Diagnosis may be difficult, and molecular assays may suffer from imperfect sensitivity. Characteristic histology and ETV4 immunohistochemical positivity are diagnostically helpful. However, ETV4 staining is unavailable in most laboratories. Here, we explored the diagnostic utility of MUC5AC immunohistochemistry in CIC-rearranged sarcomas. All 30 cases, except one, of CIC-rearranged sarcomas and 2 ATXN1-rearranged sarcomas were positive for MUC5AC, although the number of immunopositive cells was generally low (< 5%) in most samples, representing a characteristic scattered pattern. The only MUC5AC-negative case had the lowest tumor volume. Among the 110 mimicking round cell malignancies, 12 tumors showed MUC5AC positivity, including occasional cases of synovial sarcoma and small cell carcinoma, whereas the remaining 98 samples were negative. Despite its lower specificity than that of ETV4 and sparse reactivity that requires careful interpretation, MUC5AC may serve as a useful marker for CIC/ATXN1-rearranged sarcoma because of its wider accessibility.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Histopronostic factors in superficial colorectal adenocarcinomas treated by endoscopy: reproducibility and impact of immunohistochemistry and digital pathology. 通过内窥镜治疗浅表结直肠腺癌的组织前哨因素：免疫组化和数字病理学的再现性和影响。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-01-26 DOI: 10.1007/s00428-023-03722-3

Guillaume Pontarollo, Maxime Bonjour, Thomas Walter, Mathieu Pioche, Pierre-Marie Lavrut, Maud Rabeyrin, Valérie Hervieu, Tanguy Fenouil

{"title":"Histopronostic factors in superficial colorectal adenocarcinomas treated by endoscopy: reproducibility and impact of immunohistochemistry and digital pathology.","authors":"Guillaume Pontarollo, Maxime Bonjour, Thomas Walter, Mathieu Pioche, Pierre-Marie Lavrut, Maud Rabeyrin, Valérie Hervieu, Tanguy Fenouil","doi":"10.1007/s00428-023-03722-3","DOIUrl":"10.1007/s00428-023-03722-3","url":null,"abstract":"Endoscopic dissection is the first-choice treatment for superficial pT1 colorectal adenocarcinoma (sCRC). Complementary surgery decision is influenced by histopronostic factors. Prognostic significance and reproducibility of each factor are not well established. The role of immunohistochemistry (IHC) and digital pathology in this context is unknown. Our aims were (1) to evaluate each histopronostic factor reproducibility comparing HES and IHC ± digital pathology and (2) to evaluate how the different techniques would affect indications for additional surgery. We performed a single-centre retrospective study of 98 patients treated between 2010 and 2019 in Hospices Civils de Lyon, France. We analyzed physical or digital slides of HES and keratin/desmin immunostaining of 98 sCRC dissection specimens. Three pathologists evaluate the histopronostic factors including submucosal invasion depth (SMI) measured using different recommended methods. Assessment of SMI with Ueno or JSCCR methods showed good to excellent interobserver reproducibility (IOR) (ICCs of 0.858 to 0.925) using HES staining and IHC. Assessment of budding on HES sections was poorly reproducible compared to IHC which exhibit moderate IOR (κ = 0.714). IHC increased high-grade budding detection. For lymphovascular invasion and poor differentiation, the IOR was poor (κ = 0.141, 0.196 and 0.313 respectively). IHC gave a better reproducibility for further treatment indication according to JSCCR criteria (κ = 0.763) or forthcoming European guidelines (κ = 0.659). Digital pathology was equivalent to the microscope for all analyses. Histopronostic factor reproducibility in sCRC is moderate. Immunohistochemistry may facilitate the evaluation of certain criteria and improve the reproducibility of treatment decisions.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139563974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COVID-19-associated secondary sclerosing cholangitis with liver transplantation. 与 COVID-19 相关的继发性硬化性胆管炎与肝移植。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-03-25 DOI: 10.1007/s00428-024-03753-4

Anne Kristin Fischer, Dirk Stippel, Ali Canbay, Dirk Nierhoff, Michael Thomas, Jan Best, Reinhard Büttner, Uta Drebber

引用次数: 0

Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y. 具有反向极性的乳头状肾肿瘤的 7、17 和 Y 染色体发生改变的频率较低。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-06-14 DOI: 10.1007/s00428-024-03840-6

Daisuke Kiyozawa, Takeshi Iwasaki, Dai Takamatsu, Kenichi Kohashi, Takumi Miyamoto, Genshiro Fukuchi, Masatoshi Eto, Michifumi Yamashita, Yoshinao Oda

{"title":"Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y.","authors":"Daisuke Kiyozawa, Takeshi Iwasaki, Dai Takamatsu, Kenichi Kohashi, Takumi Miyamoto, Genshiro Fukuchi, Masatoshi Eto, Michifumi Yamashita, Yoshinao Oda","doi":"10.1007/s00428-024-03840-6","DOIUrl":"10.1007/s00428-024-03840-6","url":null,"abstract":"In papillary renal neoplasm with reverse polarity (PRNRP), the status of chromosomal copy number alterations, especially chromosomes 7/17 gain and chromosome Y loss, has remained controversial. In the literatures, there is a discrepancy among the results of chromosomal alteration in PRNRP depending on the analytical methods. Here, we comprehensively analyzed the status of chromosomal abnormalities in PRNRP. Nineteen PRNRP cases were analyzed by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), five of which were additionally subjected to array-based comparative genomic hybridization (aCGH) analysis. Fifteen cases of PRCC were used as controls. From the aCGH results, no genome copy number abnormalities were found in the five PRNRP cases. By FISH, numbers of nuclei with abnormal chromosomal signals in PRNRP (centromere 7 gain: 11-21% of nuclei, centromere 17 gain: 11% of nuclei, centromere Y loss: 14-31% of nuclei) were similar to those in non-neoplastic tubular cells (centromere 7 gain: 11-15% of nuclei, centromere 17 gain: 12-15% of nuclei, centromere Y loss: 13-45% of nuclei). c-MET immunohistochemical overexpression, a substitute marker for chromosome 7 trisomy, was observed in 0 of 19 PRNRP cases, consistent with the analyses by aCGH and NGS regarding chromosome 7 gain. Taken together, the frequency of chromosomal alterations in PRNRP is similar to that in non-neoplastic tubular cells, and lower than that in PRCC. Our data suggest that PRNRP has a different tumorigenesis and is a distinct entity from PRCC.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141321724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer. 免疫组织化学标志物作为多灶性前列腺癌预后的预测因子。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2023-11-28 DOI: 10.1007/s00428-023-03699-z

Laura Segalés, Nuria Juanpere, Nerea Gallarín, Marta Lorenzo, David López, Júlia Perera-Bel, Alejo Rodriguez-Vida, Lluís Fumadó, Lluís Cecchini, Joaquim Bellmunt, Josep Lloreta-Trull, Silvia Hernández-Llodrà

{"title":"Immunohistochemical markers as predictors of prognosis in multifocal prostate cancer.","authors":"Laura Segalés, Nuria Juanpere, Nerea Gallarín, Marta Lorenzo, David López, Júlia Perera-Bel, Alejo Rodriguez-Vida, Lluís Fumadó, Lluís Cecchini, Joaquim Bellmunt, Josep Lloreta-Trull, Silvia Hernández-Llodrà","doi":"10.1007/s00428-023-03699-z","DOIUrl":"10.1007/s00428-023-03699-z","url":null,"abstract":"The impact of tumor focality on prostate cancer (PCa) prognosis has been addressed in several studies with conflicting results. Tumor foci from multifocal (MF) PCa can show highly heterogeneous molecular features. Our aim was to analyze the protein expression of PTEN, SPOP, SLC45A3, ETV1, ERG and the \"triple hit\" (ERG overexpression, PTEN plus SLC45A3 loss) in unifocal (UF) and MF PCa, to evaluate their value as prognostic markers according to focality, and the role of tumor heterogeneity in MF disease. PTEN, SPOP, SLC45A3, ETV1 and ERG immunohistochemical expression was evaluated in 185 PCa from 9 TMAs, 51 UF and 134 MF. In a subset of 69 MF cases, the dominant and secondary foci (DF and SF) were compared. Heterogeneity was considered when both tumor foci presented different expression patterns. Relationship with clinicopathological features was also analyzed. MF PCa was diagnosed in significantly younger patients when compared to UF ones (p = 0.007). ETV1 overexpression was associated with UF disease (p = 0.028). A shorter time to PSA recurrence was related to SLC45A3 wt expression in UF PCa (p = 0.052), and to SPOP expression loss (p = 0.043) or \"triple hit\" phenotype in MF PCa (p = 0.041). In MF cases, PTEN loss, SLC45A3 loss and \"triple hit\" phenotype were associated with the DF and had significant heterogeneity. In conclusion, our results indicate that UF and MF PCa have relevant and consistent molecular differences. The analysis of an immunohistochemical panel, composed by PTEN, SPOP, SLC45A3, ETV1 and ERG, could be useful to predict outcome in MF cases.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138452628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases. 原发性肺癌和肺转移的诊断性胃肠道标记物。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2023-06-22 DOI: 10.1007/s00428-023-03583-w

Karina Malmros, Andreas Lindholm, Halla Vidarsdottir, Karin Jirström, Björn Nodin, Johan Botling, Johanna S M Mattsson, Patrick Micke, Maria Planck, Mats Jönsson, Johan Staaf, Hans Brunnström

{"title":"Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases.","authors":"Karina Malmros, Andreas Lindholm, Halla Vidarsdottir, Karin Jirström, Björn Nodin, Johan Botling, Johanna S M Mattsson, Patrick Micke, Maria Planck, Mats Jönsson, Johan Staaf, Hans Brunnström","doi":"10.1007/s00428-023-03583-w","DOIUrl":"10.1007/s00428-023-03583-w","url":null,"abstract":"Histopathological diagnosis of pulmonary tumors is essential for treatment decisions. The distinction between primary lung adenocarcinoma and pulmonary metastasis from the gastrointestinal (GI) tract may be difficult. Therefore, we compared the diagnostic value of several immunohistochemical markers in pulmonary tumors. Tissue microarrays from 629 resected primary lung cancers and 422 resected pulmonary epithelial metastases from various sites (whereof 275 colorectal cancer) were investigated for the immunohistochemical expression of CDH17, GPA33, MUC2, MUC6, SATB2, and SMAD4, for comparison with CDX2, CK20, CK7, and TTF-1. The most sensitive markers for GI origin were GPA33 (positive in 98%, 60%, and 100% of pulmonary metastases from colorectal cancer, pancreatic cancer, and other GI adenocarcinomas, respectively), CDX2 (99/40/100%), and CDH17 (99/0/100%). In comparison, SATB2 and CK20 showed higher specificity, with expression in 5% and 10% of mucinous primary lung adenocarcinomas and both in 0% of TTF-1-negative non-mucinous primary lung adenocarcinomas (25-50% and 5-16%, respectively, for GPA33/CDX2/CDH17). MUC2 was negative in all primary lung cancers, but positive only in less than half of pulmonary metastases from mucinous adenocarcinomas from other organs. Combining six GI markers did not perfectly separate primary lung cancers from pulmonary metastases including subgroups such as mucinous adenocarcinomas or CK7-positive GI tract metastases. This comprehensive comparison suggests that CDH17, GPA33, and SATB2 may be used as equivalent alternatives to CDX2 and CK20. However, no single or combination of markers can categorically distinguish primary lung cancers from metastatic GI tract cancer.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9730936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuroendocrine neoplasms of the breast: a review of literature. 乳腺神经内分泌肿瘤：文献综述。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 Epub Date: 2024-07-09 DOI: 10.1007/s00428-024-03856-y

Federica Vegni, Ilenia Sara De Stefano, Federica Policardo, Pietro Tralongo, Angela Feraco, Angela Carlino, Giulia Ferraro, Qianqian Zhang, Giulia Scaglione, Nicoletta D'Alessandris, Elena Navarra, Gianfranco Zannoni, Angela Santoro, Antonino Mule, Esther Diana Rossi

{"title":"Neuroendocrine neoplasms of the breast: a review of literature.","authors":"Federica Vegni, Ilenia Sara De Stefano, Federica Policardo, Pietro Tralongo, Angela Feraco, Angela Carlino, Giulia Ferraro, Qianqian Zhang, Giulia Scaglione, Nicoletta D'Alessandris, Elena Navarra, Gianfranco Zannoni, Angela Santoro, Antonino Mule, Esther Diana Rossi","doi":"10.1007/s00428-024-03856-y","DOIUrl":"10.1007/s00428-024-03856-y","url":null,"abstract":"Primary neuroendocrine neoplasms (NENs) of the breast are characterized by neuroendocrine architectural and cytological features, which must be supported by immunohistochemical positivity for neuroendocrine markers (such as Chromogranin and Synaptophysin). According to the literature, making a diagnosis of primary neuroendocrine breast cancer always needs to rule out a possible primary neuroendocrine neoplasm from another site. Currently, the latest 2022 version of the WHO of endocrine and neuroendocrine neoplasms has classified breast NENs as well-differentiated neuroendocrine tumours (NETs) and aggressive neuroendocrine carcinomas (NECs), differentiating them from invasive breast cancers of no special type (IBCs-NST). with neuroendocrine features. The current review article describes six cases from our series and a comprehensive review of the literature in the field of NENs of the breast.","PeriodicalId":23514,"journal":{"name":"Virchows Archiv","volume":null,"pages":null},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329594/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141559849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method. 更正:使用高灵敏度滴数PCR法测定乳腺癌中HER2拷贝数。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 DOI: 10.1007/s00428-023-03716-1

Beate Alinger-Scharinger, Cornelia Kronberger, Georg Hutarew, Wolfgang Hitzl, Roland Reitsamer, Frederike Klaassen-Federspiel, Martina Hager, Thorsten Fischer, Karl Sotlar, Heidi Jaksch-Bogensperger

引用次数: 0

Correction to: Programmed death-ligand 1 and tumor-infiltrating lymphocytes (TILs) - low TIL density may predict poorer long-term prognosis in T1 laryngeal cancer. 更正：程序性死亡配体 1 和肿瘤浸润淋巴细胞 (TIL) - TIL 密度低可能预示 T1 喉癌的长期预后较差。

IF 3.4 3区医学

Virchows Archiv Pub Date : 2024-08-01 DOI: 10.1007/s00428-023-03618-2

Pihla Pakkanen, Taru Ilmarinen, Elina Halme, Heikki Irjala, Petri Koivunen, Matti Pukkila, Sami Ventelä, Alhadi Almangush, Eva-Maria Birkman, Outi Lindgren, Virva Pohjolainen, Nelli Sjöblom, Caj Haglund, Jaana Hagström, Leena-Maija Aaltonen

引用次数: 0